{"id":75569,"date":"2026-08-20T12:07:09","date_gmt":"2026-08-20T04:07:09","guid":{"rendered":"https:\/\/flcube.com\/?p=75569"},"modified":"2026-08-20T12:07:10","modified_gmt":"2026-08-20T04:07:10","slug":"ascentage-pharma-1h-2026-revenue-jumps-29-to-rmb-302-million-as-olverembatinib-and-lisaftoclax-power-commercial-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75569","title":{"rendered":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ascentage Pharma Group International<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AAPG:NASDAQ\">NASDAQ: AAPG<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6855:HKG\">HKG: 6855<\/a>) reported first\u2011half 2026 <strong>revenue of RMB 302 million, up 29% year\u2011on\u2011year<\/strong>, driven primarily by higher <strong>product sales revenue<\/strong>, which climbed <strong>32.6% to RMB 282 million<\/strong>. The results underscore strengthening self\u2011sustaining cash generation from the company&#8217;s two commercial products, <strong>Olverembatinib<\/strong> and <strong>Lisaftoclax<\/strong>, alongside accelerating global expansion milestones.<\/p>\n\n\n\n<h2 id=\"h-1h-2026-financial-highlights\" class=\"wp-block-heading\">1H 2026 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>1H 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 302 million<\/td><td><strong>+29%<\/strong><\/td><\/tr><tr><td><strong>Product Sales Revenue<\/strong><\/td><td>RMB 282 million<\/td><td><strong>+32.6%<\/strong><\/td><\/tr><tr><td><strong>Commercial Products<\/strong><\/td><td>Olverembatinib, Lisaftoclax<\/td><td>Dual\u2011engine growth drivers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-dual-engine-commercial-momentum\" class=\"wp-block-heading\">Dual\u2011Engine Commercial Momentum<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Olverembatinib and Lisaftoclax<\/strong> continue to drive product sales, strengthening the company&#8217;s <strong>self\u2011sustaining cash\u2011generation capabilities<\/strong>.<\/li>\n\n\n\n<li><strong>Positive data disclosures<\/strong> from multiple pipeline assets validated the long\u2011term potential of the portfolio.<\/li>\n\n\n\n<li><strong>Several global registrational Phase III trials<\/strong> are advancing rapidly, expanding the path toward additional approvals.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-corporate-amp-globalization-milestones\" class=\"wp-block-heading\">Corporate &amp; Globalization Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>&#8220;B&#8221; Removal Completed:<\/strong> Ascentage successfully removed the &#8220;B&#8221; designation from its <strong>Hong Kong Stock Exchange<\/strong> listing during the period \u2014 a marker of sustained commercial substance under HKEX rules.<\/li>\n\n\n\n<li><strong>International Buildout:<\/strong> Expansion of the international team and acceleration of the <strong>overseas commercial layout<\/strong> proceeded across the board.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-collaborations-amp-research-partnerships\" class=\"wp-block-heading\">Global Collaborations &amp; Research Partnerships<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Partners<\/th><\/tr><\/thead><tbody><tr><td><strong>Biopharma Collaborations<\/strong><\/td><td><strong>Takeda<\/strong>, <strong>AstraZeneca<\/strong>, <strong>Merck &amp; Co., Inc.<\/strong>, <strong>Pfizer<\/strong>, <strong>Innovent<\/strong><\/td><\/tr><tr><td><strong>Academic R&amp;D Partnerships<\/strong><\/td><td><strong>Dana\u2011Farber Cancer Institute<\/strong>, <strong>Mayo Clinic<\/strong>, <strong>U.S. National Cancer Institute<\/strong>, <strong>University of Michigan<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Ascentage has established a <strong>global intellectual property portfolio<\/strong> underpinning these collaborations, reinforcing its positioning among leading biopharmaceutical companies worldwide.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Inflection:<\/strong> With revenue up 29% and product sales growing 32.6%, Ascentage is transitioning from pipeline story to sustainable commercial operator.<\/li>\n\n\n\n<li><strong>Pipeline De\u2011Risking:<\/strong> Positive readouts and advancing global Phase III registrational trials strengthen the case for future launches across the portfolio.<\/li>\n\n\n\n<li><strong>Global Credibility:<\/strong> The &#8220;B&#8221; removal, expanding international team, and blue\u2011chip partnership roster \u2014 spanning Takeda, AstraZeneca, Merck, and Pfizer \u2014 bolster the company&#8217;s profile with global investors and partners.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Ascentage Pharma&#8217;s revenue trajectory, clinical development, and commercial expansion. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Ascentage-Interim-Earnings-Call-Presentation_08.19.2026_1500.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Ascentage Interim Earnings Call Presentation_08.19.2026_1500.\"><\/object><a id=\"wp-block-file--media-459e23d5-69c1-4b19-b2c5-d145a0de92b0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Ascentage-Interim-Earnings-Call-Presentation_08.19.2026_1500.pdf\">Ascentage Interim Earnings Call Presentation_08.19.2026_1500<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Ascentage-Interim-Earnings-Call-Presentation_08.19.2026_1500.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-459e23d5-69c1-4b19-b2c5-d145a0de92b0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75571,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[200,27,985,3273],"class_list":["post-75569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-ascentage-pharma","tag-finanical-reports","tag-hkg-6855","tag-nasdaq-aapg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302 million, up 29% year\u2011on\u2011year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self\u2011sustaining cash generation from the company&#039;s two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75569\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth\" \/>\n<meta property=\"og:description\" content=\"Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302 million, up 29% year\u2011on\u2011year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self\u2011sustaining cash generation from the company&#039;s two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75569\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T04:07:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T04:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth\",\"datePublished\":\"2026-08-20T04:07:09+00:00\",\"dateModified\":\"2026-08-20T04:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2002.webp\",\"keywords\":[\"Ascentage Pharma\",\"Finanical Reports\",\"HKG: 6855\",\"NASDAQ: AAPG\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75569#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75569\",\"name\":\"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2002.webp\",\"datePublished\":\"2026-08-20T04:07:09+00:00\",\"dateModified\":\"2026-08-20T04:07:10+00:00\",\"description\":\"Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302 million, up 29% year\u2011on\u2011year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self\u2011sustaining cash generation from the company's two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75569\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75569#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth - Insight, China&#039;s Pharmaceutical Industry","description":"Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302 million, up 29% year\u2011on\u2011year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self\u2011sustaining cash generation from the company's two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75569","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth","og_description":"Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302 million, up 29% year\u2011on\u2011year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self\u2011sustaining cash generation from the company's two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.","og_url":"https:\/\/flcube.com\/?p=75569","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-20T04:07:09+00:00","article_modified_time":"2026-08-20T04:07:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75569#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75569"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth","datePublished":"2026-08-20T04:07:09+00:00","dateModified":"2026-08-20T04:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75569"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=75569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp","keywords":["Ascentage Pharma","Finanical Reports","HKG: 6855","NASDAQ: AAPG"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75569#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75569","url":"https:\/\/flcube.com\/?p=75569","name":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=75569#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=75569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp","datePublished":"2026-08-20T04:07:09+00:00","dateModified":"2026-08-20T04:07:10+00:00","description":"Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first\u2011half 2026 revenue of RMB 302 million, up 29% year\u2011on\u2011year, driven primarily by higher product sales revenue, which climbed 32.6% to RMB 282 million. The results underscore strengthening self\u2011sustaining cash generation from the company's two commercial products, Olverembatinib and Lisaftoclax, alongside accelerating global expansion milestones.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75569#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75569"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=75569#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp","width":1080,"height":608,"caption":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75569#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2002.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75569"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75569\/revisions"}],"predecessor-version":[{"id":75572,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75569\/revisions\/75572"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/75571"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}